JAMA MAY 27, 1998

Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels

Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr

Bottom Line

The AFCAPS/TexCAPS trial demonstrated that treatment with lovastatin significantly reduced the risk of first acute major coronary events in individuals with average LDL-C and below-average HDL-C levels who had no prior clinical evidence of cardiovascular disease.

Key Findings

1. Lovastatin treatment was associated with a 37% reduction in the relative risk of the primary endpoint (fatal or nonfatal myocardial infarction, unstable angina, or sudden cardiac death) compared to placebo (RR 0.63; 95% CI 0.50-0.79; P < 0.001).

2. Absolute risk reduction for the primary endpoint was 2.2% in men and 1.2% in women over the course of the study.

3. Treatment resulted in significant improvements in lipid profiles at 1 year: a 25% reduction in LDL-C, an 18% reduction in total cholesterol, a 15% reduction in triglycerides, and a 6% increase in HDL-C compared to baseline.

4. The number needed to treat (NNT) over 5 years to prevent one primary endpoint event was 46 for men and 88 for women.

5. Benefit was observed across various subgroups, including participants younger than 65 years and those with multiple risk factors.

Study Design

Design

RCT

Double-Blind

Sample

6,605

Patients

Duration

5.2 yr

Median

Setting

Multicenter, US

Population Men aged 45-73 and women aged 55-73 with no evidence of atherosclerotic cardiovascular disease, with average LDL-C (130-190 mg/dL) and below-average HDL-C (≤45 mg/dL for men, ≤47 mg/dL for women).

Intervention Lovastatin 20-40 mg daily

Comparator Placebo

Outcome First occurrence of an acute major coronary event (defined as fatal or nonfatal myocardial infarction, unstable angina, or sudden cardiac death)

Study Limitations

• The trial was conducted in a relatively low-to-moderate-risk population, which may limit the generalizability of findings to higher-risk primary prevention populations.

• While the reduction in primary events among women was 46%, this did not reach statistical significance, likely due to the small number of events in the female subgroup.

• The study design may have included participants who might not have met clinical criteria for statin initiation under more stringent, contemporary NCEP guidelines at the time of study, though it served to broaden the evidence base.

• The follow-up period, while sufficient (mean 5.2 years), may not capture very long-term safety or benefit outcomes for primary prevention populations.

Clinical Significance

AFCAPS/TexCAPS was a landmark trial that provided essential evidence for the use of statins in primary prevention for patients who do not have established cardiovascular disease but exhibit lipid profiles characterized by average LDL-C and low HDL-C. It helped expand the paradigm for lipid-lowering therapy beyond high-risk or secondary prevention, establishing that pharmacologic intervention could safely and effectively reduce acute coronary events in broader, lower-risk cohorts.

Historical Context

Prior to AFCAPS/TexCAPS, the benefit of statin therapy was largely established in secondary prevention trials and among high-risk patients. This trial was the first major study to test the hypothesis that statin therapy could provide significant primary prevention benefits in a population of men and women with 'average' lipid levels who otherwise lacked evidence of atherosclerotic cardiovascular disease, fundamentally shifting the approach to preventive cardiology.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the biochemical mechanism of action of lovastatin, and how does this intervention specifically address the pathophysiology of atherosclerosis in a patient with 'average' LDL levels?

Key Response

Lovastatin is an HMG-CoA reductase inhibitor that prevents the conversion of HMG-CoA to mevalonate, the rate-limiting step in cholesterol synthesis. By reducing intra-hepatocyte cholesterol, it upregulates LDL-receptor expression, increasing clearance of circulating LDL. In 'average' LDL patients, the benefit likely stems from both this reduction and 'pleiotropic effects,' such as improved endothelial function, reduced inflammation, and plaque stabilization, which prevent the transition from a stable plaque to an acute coronary event.

Resident

The AFCAPS/TexCAPS trial included participants with low HDL-C. How does the presence of low HDL-C modify the cardiovascular risk profile in a primary prevention patient with an LDL-C level between 130-150 mg/dL?

Key Response

AFCAPS/TexCAPS demonstrated that patients with 'average' LDL-C (mean 150 mg/dL) but 'below-average' HDL-C (mean 36 mg/dL in men) derive significant benefit from statins. Low HDL-C is an independent risk factor for ASCVD. This study was pivotal in showing that absolute LDL-C levels should not be the sole determinant for primary prevention, leading to the integration of more comprehensive risk assessment tools that include HDL-C as a critical variable.

Fellow

AFCAPS/TexCAPS was one of the first major trials to show a reduction in unstable angina as part of a composite endpoint. How does this finding influence the contemporary interpretation of 'hard' vs 'soft' cardiac endpoints in primary prevention trials?

Key Response

The trial showed a 37% reduction in the first acute major coronary event, significantly driven by a reduction in unstable angina (32%) and MI (40%). While 'hard' endpoints like CV mortality are preferred, AFCAPS/TexCAPS highlighted that 'softer' endpoints like unstable angina represent a significant clinical and economic burden, justifying their inclusion in composite outcomes to ensure trials are adequately powered in lower-risk primary prevention cohorts.

Attending

Given that AFCAPS/TexCAPS targeted a population that many clinicians at the time would have monitored without intervention, how should these results influence your discussion with a 50-year-old patient who has no symptoms but a 'borderline' 10-year ASCVD risk?

Key Response

The study provides evidence-based reassurance that treating 'average' lipid profiles can prevent the first major coronary event (NNT of approximately 50 over 5 years). It serves as a teaching point for the 'prevention paradox': while the individual risk might be low, the population-wide benefit of treating this large 'average' cohort is substantial. It supports early intervention to shift the risk curve before clinical disease manifests.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

AFCAPS/TexCAPS utilized a sequential screening process that excluded a large percentage of the initially screened population. What are the implications of this 'run-in' or highly selective screening phase on the estimation of the treatment's effect size and its generalizability to a real-world primary care setting?

Key Response

The trial screened over 90,000 people to enroll 6,605. This high level of selection (e.g., specific HDL/LDL ranges, dietary compliance) minimizes 'noise' and maximizes the ability to detect a signal (internal validity), but it often results in an overestimation of the treatment effect compared to a real-world setting where adherence is lower and the population is more heterogeneous (external validity).

Journal Editor

As a reviewer, how would you critically evaluate the decision to terminate a primary prevention trial like AFCAPS/TexCAPS based on a composite endpoint if the reduction in total mortality was not yet statistically significant?

Key Response

Reviewers would flag that while the composite endpoint (MI, unstable angina, SCD) was highly significant (p < 0.001), the study was not powered to detect a difference in total mortality. Terminating early or focusing solely on the composite can be seen as 'endpoint inflation.' However, in primary prevention, achieving a mortality benefit requires much longer follow-up; thus, the significant reduction in acute morbid events is considered sufficiently practice-changing to justify the editorial significance.

Guideline Committee

How did the AFCAPS/TexCAPS data specifically inform the transition from the NCEP ATP II (lipid-threshold based) to subsequent risk-based guidelines, and how does it align with the current 2018 AHA/ACC multi-symbol risk assessment?

Key Response

AFCAPS/TexCAPS provided the evidentiary bridge from treating only overt hyperlipidemia to treating based on global risk. Current AHA/ACC guidelines (2018) recommend statins for primary prevention in adults aged 40-75 with LDL 70-189 mg/dL and a 10-year ASCVD risk of >=7.5%. AFCAPS/TexCAPS participants, despite 'average' LDL, would likely have met these risk thresholds due to their low HDL and age, validating the shift from 'treating the number' to 'treating the risk.'

Clinical Landscape

Noteworthy Related Trials

1994

4S Study

n = 4,444 · Lancet

Tested

Simvastatin

Population

Patients with angina or prior MI and high cholesterol

Comparator

Placebo

Endpoint

Total mortality

Key result: Simvastatin significantly reduced total mortality and major coronary events in patients with coronary heart disease.

1995

WOSCOPS Trial

n = 6,595 · NEJM

Tested

Pravastatin

Population

Middle-aged men with hypercholesterolemia but no history of MI

Comparator

Placebo

Endpoint

Nonfatal MI or death from coronary heart disease

Key result: Pravastatin therapy resulted in a significant reduction in the primary endpoint of nonfatal MI or coronary death.

2004

CARDS Trial

n = 2,838 · Lancet

Tested

Atorvastatin 10mg daily

Population

Patients with T2DM and no history of CVD

Comparator

Placebo

Endpoint

Major cardiovascular events

Key result: Atorvastatin significantly reduced the risk of first major cardiovascular events in diabetic patients with average cholesterol levels.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis